Leerink Swann ups Eli Lilly (LLY +5.3%) to Outperform and raises sales estimates on the back of...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Leerink Swann ups Eli Lilly (LLY +5.3%) to Outperform and raises sales estimates on the back of positive trial results for its gastric cancer treatment, ramucirumab. The firm thinks the recently released data shows encouraging potential for use on other tumor types, which could boost sales and lower the drug's overall marketing risk outlook.